Announced details
Treatment of amyotrophic lateral sclerosis (ALS)
Approx. 300,000 patients worldwide; approx. 10,000 patients in Japan
The parties have collaborated on the development of ALS treatments since 2017. They conducted joint research, and VIS acquired the rights to 2 nucleic acid drugs from The Jikei University School of Medicine, making VIS the patent applicant and rights holder. Both parties will bear their own research costs, and no payments or other transfers of value are planned.
Minato-ku, Tokyo. The Department of Regenerative Medicine is part of the Center for Integrated Medical Research, and its professor is Okano James Hirotaka (岡野ジェイムス洋尚). The department conducts ALS research and analyses using human iPSC models and pathological sections.
Application number: 特願2025-575964; international application number: PCT/JP2025/025230. Rights granted in Japan. Registration number and validity period: Not disclosed.
No change to the earnings forecast for the year ending December 2026. The development is expected to contribute to the enhancement of corporate value over the medium to long term.
The company does not address Contract Value / Offering price.
Paper published in the Journal of Cell Biology: “Dominant-negative isoform of TDP-43 is regulated by ALS-linked RNA-binding proteins”
| Item | Details |
|---|---|
| Names of Products / Services Covered | Nucleic acid drug and its use, TDP-43 MP13 |
| Counterparty | The Jikei University School of Medicine, Center for Integrated Medical Research, Department of Regenerative Medicine |
| Counterparty overview | Minato-ku, Tokyo. The Department of Regenerative Medicine is part of the Center for Integrated Medical Research, and its professor is Okano James Hirotaka (岡野ジェイムス洋尚). The department conducts ALS research and analyses using human iPSC models and pathological sections. |
| Relationship with the Company | The parties have collaborated on the development of ALS treatments since 2017. They conducted joint research, and VIS acquired the rights to 2 nucleic acid drugs from The Jikei University School of Medicine, making VIS the patent applicant and rights holder. Both parties will bear their own research costs, and no payments or other transfers of value are planned. |
| Applicable area | Treatment of amyotrophic lateral sclerosis (ALS) |
| Registration number and expiry date | Application number: 特願2025-575964; international application number: PCT/JP2025/025230. Rights granted in Japan. Registration number and validity period: Not disclosed. |
| Usage history | Approx. 300,000 patients worldwide; approx. 10,000 patients in Japan |
| Impact on Business Performance | No change to the earnings forecast for the year ending December 2026. The development is expected to contribute to the enhancement of corporate value over the medium to long term. |
| Source | Paper published in the Journal of Cell Biology: “Dominant-negative isoform of TDP-43 is regulated by ALS-linked RNA-binding proteins” |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because, following examination, patent rights for the substance patent were granted in Japan.